BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
You finally got a doctor's appointment. Here's how to get the most out of it - 2James Webb Space Telescope spies mysterious high-energy radiation in star nursery
- 3What to expect from the planets in 2026 — key dates and sky events
- 4US FDA grants market authorization to six on! PLUS nicotine pouch products
- 5Unusual 'ingredients' helped stars form in a galaxy near the Milky Way
- Former GLP-1 users regain lost weight after about 18 months, study says
- Embrace the Outside: Exercises and Entertainment
- Spots To Go Birdwatching All over the Planet
- How a toxic self-improvement trend with a funny name took over your feed
- Voting begins in Uganda’s presidential election during internet shutdown and polling station delays
- Find Your Ideal Tea: Six Particular Assortments
- Father and son spending Christmas together after health scares
- Hitting the brakes: Hubble Space Telescope watches doomed comet reverse its spin
- EU health regulator urges immediate vaccinations amid early surge in flu cases
